{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T15:15:08Z","timestamp":1788189308019,"version":"build-2803163510"},"reference-count":56,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline Plc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-global.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology: Global"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jacig.2026.100741","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T16:41:17Z","timestamp":1780332077000},"page":"100741","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effect of once-daily ICS\/LAMA\/LABA triple therapy versus ICS\/LABA on respiratory symptoms (E-RS: Asthma): Analysis of the phase IIIA CAPTAIN trial"],"prefix":"10.1016","volume":"5","author":[{"given":"Emilio","family":"Pizzichini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Brusselle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jodie","family":"Crawford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromasa","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huib A.M.","family":"Kerstjens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Oppenheimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Papi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian D.","family":"Pavord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Slade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liza","family":"Yuanita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacig.2026.100741_bib1","series-title":"Global strategy for asthma management and prevention","year":"2025"},{"key":"10.1016\/j.jacig.2026.100741_bib2","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s12931-016-0374-z","article-title":"Determinants and impact of suboptimal asthma control in Europe: the international cross-sectional and longitudinal assessment on asthma control (LIASON) study","volume":"17","author":"Braido","year":"2016","journal-title":"Respir Res"},{"key":"10.1016\/j.jacig.2026.100741_bib3","article-title":"Asthma control is associated with economic outcomes, work productivity and health-related quality of life in patients with asthma","volume":"7","author":"Lee","year":"2020","journal-title":"BMJ Open Respir Res"},{"key":"10.1016\/j.jacig.2026.100741_bib4","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1136\/thorax-2021-217032","article-title":"Asthma exacerbations are associated with a decline in lung function: a longitudinal population-based study","volume":"78","author":"Soremekun","year":"2023","journal-title":"Thorax"},{"key":"10.1016\/j.jacig.2026.100741_bib5","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00588-2019","article-title":"Management of severe asthma: a European Respiratory Society\/American Thoracic Society guideline","volume":"55","author":"Holguin","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jacig.2026.100741_bib6","series-title":"2020 focused updates to the asthma management guidelines: a report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group","year":"2020"},{"key":"10.1016\/j.jacig.2026.100741_bib7","series-title":"Asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN)","year":"2024"},{"key":"10.1016\/j.jacig.2026.100741_bib8","series-title":"Asthma prevention and management guidelines 2024","year":"2024"},{"key":"10.1016\/j.jacig.2026.100741_bib9","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S2213-2600(20)30389-1","article-title":"Efficacy and safety of once-daily single-inhaler triple therapy (FF\/UMEC\/VI) versus FF\/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial","volume":"9","author":"Lee","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jacig.2026.100741_bib10","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.chest.2024.02.029","article-title":"International variation in severe exacerbation rates in patients with severe asthma","volume":"166","author":"Lee","year":"2024","journal-title":"Chest"},{"key":"10.1016\/j.jacig.2026.100741_bib11","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12890-017-0409-3","article-title":"The frequency of asthma exacerbations and healthcare utilization in patients with asthma from the UK and USA","volume":"17","author":"Suruki","year":"2017","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.jacig.2026.100741_bib12","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1016\/j.jaip.2019.04.019","article-title":"Association between pulmonary function and asthma symptoms","volume":"7","author":"Sullivan","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jacig.2026.100741_bib13","doi-asserted-by":"crossref","DOI":"10.1177\/17534666241254212","article-title":"Relationships between symptoms and lung function in asthma and\/or chronic obstructive pulmonary disease in a real-life setting: the NOVEL observational longiTudinal studY","volume":"18","author":"Papi","year":"2024","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.jacig.2026.100741_bib14","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/S0149-2918(02)85133-5","article-title":"Effect of montelukast, a once-daily leukotriene receptor antagonist, on peak expiratory flow variability","volume":"24","author":"Zhang","year":"2002","journal-title":"Clin Ther"},{"key":"10.1016\/j.jacig.2026.100741_bib15","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s41687-021-00338-6","article-title":"Measuring respiratory symptoms in moderate\/severe asthma: evaluation of a respiratory symptom tool, the E-RS\u00ae: COPD in asthma populations","volume":"5","author":"Tabberer","year":"2021","journal-title":"J Patient Rep Outcomes"},{"key":"10.1016\/j.jacig.2026.100741_bib16","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s12931-014-0124-z","article-title":"Measuring respiratory symptoms of COPD: performance of the EXACT- Respiratory Symptoms Tool (E-RS) in three clinical trials","volume":"15","author":"Leidy","year":"2014","journal-title":"Respir Res"},{"key":"10.1016\/j.jacig.2026.100741_bib17","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12931-019-1070-6","article-title":"Reliability, validity and responsiveness of E-RS:COPD in patients with spirometric asthma-COPD overlap","volume":"20","author":"Nelsen","year":"2019","journal-title":"Respir Res"},{"key":"10.1016\/j.jacig.2026.100741_bib18","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1034\/j.1399-3003.1999.14d29.x","article-title":"Development and validation of a questionnaire to measure asthma control","volume":"14","author":"Juniper","year":"1999","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jacig.2026.100741_bib19","series-title":"Trelegy Ellipta\u2014Highlights of prescribing information","year":"2017"},{"key":"10.1016\/j.jacig.2026.100741_bib20","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.alit.2023.02.006","article-title":"Executive summary: Japanese guidelines for adult asthma (JGL) 2021","volume":"72","author":"Niimi","year":"2023","journal-title":"Allergol Int"},{"key":"10.1016\/j.jacig.2026.100741_bib21","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1164\/rccm.202402-0368OC","article-title":"Association of dose of inhaled corticosteroids and frequency of adverse events","volume":"211","author":"Bloom","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jacig.2026.100741_bib22","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jaip.2025.10.005","article-title":"Association of stepping up to high-dose inhaled corticosteroids and risk of future asthma exacerbations: data from the United States","volume":"14","author":"Tran","year":"2026","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jacig.2026.100741_bib23","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.04233-2020","article-title":"Triple therapy in uncontrolled asthma: a network meta-analysis of phase III studies","volume":"58","author":"Rogliani","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jacig.2026.100741_bib24","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1001\/jama.2021.7872","article-title":"Triple vs dual inhaler therapy and asthma outcomes in moderate to severe asthma: a systematic review and meta-analysis","volume":"325","author":"Kim","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.jacig.2026.100741_bib25","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.anai.2023.08.609","article-title":"Consensus of an American College of Allergy, Asthma, and Immunology, American Academy of Allergy, Asthma, and Immunology, and American Thoracic Society workgroup on definition of clinical remission in asthma on treatment","volume":"131","author":"Blaiss","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jacig.2026.100741_bib26","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jaci.2019.12.006","article-title":"An expert consensus framework for asthma remission as a treatment goal","volume":"145","author":"Menzies-Gow","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jacig.2026.100741_bib27","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/S2213-2600(21)00004-7","article-title":"The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study","volume":"9","author":"McDowell","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jacig.2026.100741_bib28","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.jaci.2025.05.031","article-title":"Analysis of airway inflammation demonstrates a mechanism for T2-biologic failure in asthma","volume":"156","author":"McDowell","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jacig.2026.100741_bib29","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/j.jaip.2019.02.021","article-title":"Role and impact of chronic cough in individuals with asthma from the general population","volume":"7","author":"\u00c7olak","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jacig.2026.100741_bib30","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1016\/j.jaip.2018.01.016","article-title":"Tiotropium attenuates refractory cough and capsaicin cough reflex sensitivity in patients with asthma","volume":"6","author":"Fukumitsu","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jacig.2026.100741_bib31","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.anai.2023.03.032","article-title":"Tiotropium for refractory cough in asthma via cough reflex sensitivity: a randomized, parallel, open-label trial","volume":"131","author":"Fukumitsu","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jacig.2026.100741_bib32","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1080\/02770903.2025.2455416","article-title":"The efficacy and safety of fluticasone furoate\/umeclidinium\/vilanterol (FF\/UMEC\/VI) on cough symptoms in adult patients with asthma, a randomized double-blind, placebo-controlled, parallel group study: Chronic Cough in Asthma (COCOA) study","volume":"62","author":"Tagaya","year":"2025","journal-title":"J Asthma"},{"key":"10.1016\/j.jacig.2026.100741_bib33","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1014350","article-title":"Effect of bronchoconstriction on airway remodeling in asthma","volume":"364","author":"Grainge","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacig.2026.100741_bib34","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1136\/thoraxjnl-2014-205731","article-title":"Tiotropium attenuates IL-13-induced goblet cell metaplasia of human airway epithelial cells","volume":"70","author":"Kistemaker","year":"2015","journal-title":"Thorax"},{"key":"10.1016\/j.jacig.2026.100741_bib35","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01247-2017","article-title":"The mode of action of anticholinergics in asthma","volume":"52","author":"Gosens","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jacig.2026.100741_bib36","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0196-2021","article-title":"The impact of long-acting muscarinic antagonists on mucus hypersecretion and cough in chronic obstructive pulmonary disease: a systematic review","volume":"31","author":"Calzetta","year":"2022","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.jacig.2026.100741_bib37","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1111\/cea.13015","article-title":"Corticosteroid and long-acting \u00df-agonist therapy reduces epithelial goblet cell metaplasia","volume":"47","author":"Lachowicz-Scroggins","year":"2017","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jacig.2026.100741_bib38","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0091-6749(06)80008-4","article-title":"A comparative study of the effects of an inhaled corticosteroid, budesonide, and a beta 2-agonist, terbutaline, on airway inflammation in newly diagnosed asthma: a randomized, double-blind, parallel-group controlled trial","volume":"90","author":"Laitinen","year":"1992","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jacig.2026.100741_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2500\/ajra.2012.26.3716","article-title":"Acquired cilia dysfunction in chronic rhinosinusitis","volume":"26","author":"Gudis","year":"2012","journal-title":"Am J Rhinol Allergy"},{"key":"10.1016\/j.jacig.2026.100741_bib40","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12931-020-01601-y","article-title":"Gastroesophageal reflux disease is a risk factor for sputum production in the general population: the Nagahama study","volume":"22","author":"Morimoto","year":"2021","journal-title":"Respir Res"},{"key":"10.1016\/j.jacig.2026.100741_bib41","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41572-018-0042-3","article-title":"Bronchiectasis","volume":"4","author":"Chalmers","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jacig.2026.100741_bib42","doi-asserted-by":"crossref","first-page":"512","DOI":"10.3109\/02770903.2014.975358","article-title":"Effects of regular treatment with combination of salmeterol\/fluticasone propionate and salmeterol alone in cough variant asthma","volume":"52","author":"Tagaya","year":"2015","journal-title":"J Asthma"},{"key":"10.1016\/j.jacig.2026.100741_bib43","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1006\/pupt.2000.0264","article-title":"Effects of inhaled corticosteroids on cough threshold in patients with bronchial asthma","volume":"14","author":"Di Franco","year":"2001","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.jacig.2026.100741_bib44","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.chest.2019.12.021","article-title":"Managing chronic cough due to asthma and NAEB in adults and adolescents: CHEST guideline and expert panel report","volume":"158","author":"Cote","year":"2020","journal-title":"Chest"},{"key":"10.1016\/j.jacig.2026.100741_bib45","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.anai.2020.12.015","article-title":"Real-world evidence: patient views on asthma in respiratory specialist clinics in America","volume":"126","author":"Oppenheimer","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jacig.2026.100741_bib46","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1016\/j.jaip.2022.03.027","article-title":"Long-term use of short-acting beta(2)-agonists in patients with adult-onset asthma","volume":"10","author":"Vahatalo","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jacig.2026.100741_bib47","article-title":"Systemic adverse effects from inhaled corticosteroid use in asthma: a systematic review","volume":"7","author":"Patel","year":"2020","journal-title":"BMJ Open Respir Res"},{"key":"10.1016\/j.jacig.2026.100741_bib48","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.jaip.2022.10.040","article-title":"Effect of stepping up to high-dose inhaled corticosteroids in patients with asthma: UK database study","volume":"11","author":"Pavord","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jacig.2026.100741_bib49","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta(2)-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jacig.2026.100741_bib50","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.jaci.2013.05.020","article-title":"Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia","volume":"132","author":"Laviolette","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jacig.2026.100741_bib51","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-2600(15)00042-9","article-title":"Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials","volume":"3","author":"Castro","year":"2015","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jacig.2026.100741_bib52","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacig.2026.100741_bib53","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1056\/NEJMoa0805435","article-title":"Mepolizumab for prednisone-dependent asthma with sputum eosinophilia","volume":"360","author":"Nair","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacig.2026.100741_bib54","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S2213-2600(17)30344-2","article-title":"Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies","volume":"6","author":"FitzGerald","year":"2018","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jacig.2026.100741_bib55","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S2213-2600(16)30031-5","article-title":"Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies","volume":"4","author":"Ortega","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jacig.2026.100741_bib56","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.jaci.2006.01.011","article-title":"Asthma Control Test: reliability, validity, and responsiveness in patients not previously followed by asthma specialists","volume":"117","author":"Schatz","year":"2006","journal-title":"J Allergy Clin Immunol"}],"container-title":["Journal of Allergy and Clinical Immunology: Global"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772829326001037?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772829326001037?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T14:24:47Z","timestamp":1788186287000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772829326001037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":56,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2772829326001037"],"URL":"https:\/\/doi.org\/10.1016\/j.jacig.2026.100741","relation":{},"ISSN":["2772-8293"],"issn-type":[{"value":"2772-8293","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of once-daily ICS\/LAMA\/LABA triple therapy versus ICS\/LABA on respiratory symptoms (E-RS: Asthma): Analysis of the phase IIIA CAPTAIN trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology: Global","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacig.2026.100741","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}],"article-number":"100741"}}